MED15

Across TCGA pan-cancer cohorts, MED15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MED15 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MED15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED15 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

LUSC, LUAD, and UCEC are the cancer types where MED15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.001	0.684	<.001	24	view →
LUAD	OS	Median	All	0.150	0.788	<.001	18	view →
UCEC	DFS	Median	All	0.972	0.829	.028	6	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MED15–LUSC (OS)

Open the LUSC breakdown →